Forbes August 3, 2020
Steven Salzberg

I wrote a blog post over the weekend that has generated tremendous pushback, including an op-ed in the New York Times as well as thousands of comments on Twitter.

In my previous post, I suggested that while we’re pursuing Phase 3 testing of several promising Covid-19 vaccines, we could simultaneously offer those same, unapproved vaccines to a wider community of volunteers, as long as those volunteers were fully informed. The benefits of moving quickly, I argued, would outweigh the risks.

I was wrong. After reading many of the responses to my article, some of them outlining the risks in greater detail, I have concluded that (1) the risks are greater than I presented them, and (2) the benefits are not...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
The Ripple Effect: Ways to Make Health in All Policies Stick in Kansas and Beyond to Enhance Health and Equity
Research Funding Is Needed To Support An Effective, Equitable, And Sustainable Public Health System
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
New Data: Long COVID Cases Surge
New federal health IT strategy increases focus on public health, AI

Share This Article